Navigation Links
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
Date:5/8/2008

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Bank of America 2008 Healthcare Conference on May 14, 2008 at 5:20 p.m. Pacific Time (8:20 p.m. Eastern Time) at the Four Seasons Hotel in Las Vegas, Nevada. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available until May 30, 2008. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

For
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... theatergoers have shelled out for crude 3-D glasses, ... viewing experience. These basic devices, used to trick ... may soon be rendered obsolete with the introduction ... University researchers. , TAU doctoral students Yuval Yifat, ... efficient holography based on nanoantennas that could be ...
(Date:1/15/2014)... to assembling a club sandwich at the nanoscale, ... have succeeded in crafting a uniform, multi-walled carbon-nanotube-based ... commonly used in upholstered furniture and other soft ... foam was reduced 35 percent compared with untreated ...
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
Breaking Biology Technology:Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3
... 30 , - 76% Higher ... Control Versus Lantus(R) , Sanofi-aventis (EURONEXT: ... a,head-to-head study providing further evidence on the efficacy of once-daily,24-hour ... detemir. The study was presented during the 45th,Annual Meeting of ...
... Dr. John McPherson, Platform Leader, Cancer Genomics and High-Throughput ... Ontario Institute for Cancer Research (OICR) led a team ... the NEBNext(TM) DNA Sample Prep Reagents for use with ... the evaluation, "We are constantly striving for the best ...
... physicists have created the first atomic-scale maps of ... of producing "designer dots" that can be tailored ... atoms or nanoparticles---are tiny semiconductor crystals with wide-ranging ... and other technologies. Each dot is a well-ordered ...
Cached Biology Technology:Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2U-M physicists create first atomic-scale map of quantum dots 2
(Date:7/10/2014)... of overfishing in the English Channel has resulted in ... and left fishermen ,scraping the barrel, for increasing amounts ... cod, haddock and many other species at the head ... many removed from the area completely., These are some ... biologists at Plymouth University, in association with international non-profit ...
(Date:7/10/2014)... even if you are a big, bad sea scorpion. ... shallow waters for any prey in sight. The next, ... scientists, you,re reduced to trolling for weaker, soft-bodied animals ... lot of the giant pterygotid eurypterid, the largest arthropod ... published in the journal Biology Letters , dramatically ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
Breaking Biology News(10 mins):Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 3Extinct sea scorpion gets a Yale eye exam, with surprising results 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... Clinic,s Genomic Medicine Institute have revealed multiple genetic discoveries that ... patients who are predisposed to breast and kidney cancer. ... cancerous tumors, is published in the Dec. 22 issue of ... JAMA ). Charis Eng, M.D., Ph.D, Chair of ...
... The leading causes of death have shifted from infectious diseases ... illnesses may be affected by diet. In a study published ... the American Dietetic Association , researchers investigated empirical data regarding ... the eating patterns of over 2500 adults between the ages ...
... , ARLINGTON, Va. Dubbed the "Brilliant 10" by ... 2010 list of top young scientists have received funding ... two ONR-funded researchers are Dr. Chiara Daraio, a 2010 ... and designed a nonlinear acoustic lens, which has the ...
Cached Biology News:Researchers discover genetic predisposition for breast, kidney cancers 2Eating healthier means living longer 2ONR-funded researchers among Popular Science magazine's 'Brilliant 10' 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Full length YebU (Escherichia coli)...
Request Info...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: